Safety and Efficacy of Autologous PRP and PPP Eye Drops in the Treatment of Ocular GVHD

Inclusion Criteria: * Age ≥18 years. * Willing and able to provide written informed consent. * Willing and able to comply with study assessments for the full duration of the study. * Diagnosis of ocular GVHD. * Minimum corneal fluorescein staining of 4 (NEI grading scheme, 0-15) in at least one eye. * In good stable overall health. Exclusion Criteria: * Remission from primary cancer in more than 5 years. * History of thrombocytopenia (platelet\<50,000) in the last 2 weeks before study entry. * Ocular or periocular malignancy. * Significant change, as judged by the PI, in systemic immunosuppressive regimen before 2 weeks of study entry. * Any change in dosage of tetracycline compounds (tetracycline, doxycycline, and minocycline) within the last month. * Any change in frequency of preserved anti-glaucoma medications before 2 weeks of study entry. * Current use of topical steroids more than twice a day. * Change in frequency of topical cyclosporine and/or topical kineret within the last month. * Signs of current infection, including fever and current treatment with antibiotics. * Intra-ocular surgery or ocular laser surgery within the last 3 months. * Has worn contact lenses, except for bandage contact lens or rigid gas permeable lens or scleral contact lens, for the last 2 weeks prior to the study or would be unable to stay off contact lenses for the study duration. * Any condition (including language barrier) that precludes patient's ability to comply with study requirements including completion of study.